47,879 Shares in NewAmsterdam Pharma Company N.V. $NAMS Purchased by Mizuho Markets Cayman LP

Mizuho Markets Cayman LP purchased a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 47,879 shares of the company’s stock, valued at approximately $1,680,000.

A number of other large investors have also recently made changes to their positions in NAMS. Jennison Associates LLC boosted its position in NewAmsterdam Pharma by 42.5% in the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after buying an additional 1,252,451 shares during the period. Atle Fund Management AB boosted its position in NewAmsterdam Pharma by 23.2% in the 3rd quarter. Atle Fund Management AB now owns 193,625 shares of the company’s stock valued at $5,507,000 after buying an additional 36,402 shares during the period. Capital World Investors boosted its position in NewAmsterdam Pharma by 17.1% in the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock valued at $279,358,000 after buying an additional 1,434,986 shares during the period. Handelsbanken Fonder AB boosted its position in NewAmsterdam Pharma by 18.8% in the 3rd quarter. Handelsbanken Fonder AB now owns 405,800 shares of the company’s stock valued at $11,541,000 after buying an additional 64,200 shares during the period. Finally, Keybank National Association OH purchased a new stake in NewAmsterdam Pharma in the 3rd quarter valued at about $455,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $35.44 on Friday. The company has a 50 day moving average price of $32.76 and a 200-day moving average price of $34.25. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $16.78 and a fifty-two week high of $42.21. The stock has a market capitalization of $4.14 billion, a PE ratio of -19.80 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The business had revenue of $3.04 million during the quarter. Equities research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.76 EPS for the current year.

Analyst Ratings Changes

NAMS has been the subject of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st. Guggenheim boosted their price objective on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Truist Financial initiated coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 price objective for the company. HC Wainwright raised shares of NewAmsterdam Pharma to a “strong-buy” rating in a research report on Thursday, February 19th. Finally, Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $48.00.

Insider Transactions at NewAmsterdam Pharma

In other news, Director Louis G. Lange sold 44,619 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $30.42, for a total value of $1,357,309.98. Following the completion of the sale, the director owned 10,360 shares of the company’s stock, valued at approximately $315,151.20. This represents a 81.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael H. Davidson sold 443,707 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the completion of the sale, the chief executive officer directly owned 174,144 shares of the company’s stock, valued at $5,790,288. The trade was a 71.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 1,122,805 shares of company stock valued at $36,606,033. Company insiders own 12.74% of the company’s stock.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.